Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-1ff94cd25db3b18c09de52395c558d2d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-1ff94cd25db3b18c09de52395c558d2d",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-1ff94cd25db3b18c09de52395c558d2d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-1ff94cd25db3b18c09de52395c558d2d\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-1ff94cd25db3b18c09de52395c558d2d</b></p><a name=\"composition-en-1ff94cd25db3b18c09de52395c558d2d\"> </a><a name=\"hccomposition-en-1ff94cd25db3b18c09de52395c558d2d\"> </a><a name=\"composition-en-1ff94cd25db3b18c09de52395c558d2d-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1768/001-005</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - vanflyta</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1768/001-005"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp1ff94cd25db3b18c09de52395c558d2d"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - vanflyta",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What VANFLYTA is and what it is used for</li><li>What you need to know before you take VANFLYTA</li><li>How to take VANFLYTA</li><li>Possible side effects</li><li>How to store VANFLYTA</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What vanflyta is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What vanflyta is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What VANFLYTA is VANFLYTA contains the active substance quizartinib. It is a type of cancer medicine called a protein kinase inhibitor . The medicine is used along with chemotherapy to treat adults who have acute myeloid leukaemia (AML, a type of blood cancer), with a mutation (change) in the FLT3 gene called FLT3-ITD . VANFLYTA treatment may be continued also after a bone marrow transplant when patients have sufficiently recovered.</p><p>Your doctor will test your cancer cells for changes in the FLT3 gene to look for FLT3-ITD mutations beforehand to make sure that VANFLYTA is right for you.</p><p>How VANFLYTA works In AML, the body makes a large amount of abnormal white blood cells that do not mature to become healthy cells. VANFLYTA works by blocking the action of proteins called tyrosine kinases in these abnormal cells. This slows down or stops the abnormal cells from dividing and growing uncontrollably, and helps immature cells grow into normal cells.</p></div>"
}
},
{
"title" : "2. What you need to know before you take vanflyta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take vanflyta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take VANFLYTA</p><ul><li>if you are allergic to quizartinib or any of the other ingredients in this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.</li><li>if you were born with a heart problem called long QT syndrome (abnormal electrical activity of the heart that affects its rhythm).</li><li>if you are breast-feeding (see Pregnancy, breast-feeding and fertility ). Warnings and precautions Talk to your doctor, pharmacist or nurse before taking VANFLYTA:</li><li>if you have or have had any heart problems including arrhythmia (abnormal heart rhythm), myocardial infarction (heart attack) within 6 months, congestive heart failure (heart isn t pumping hard enough), uncontrolled angina pectoris (chest pain) or uncontrolled hypertension (blood pressure that s too high).</li><li>if you have been told you have low blood levels of potassium or magnesium.</li><li>if you are taking medicines that can prolong the QT interval (irregular heart rhythm; see Other medicines and VANFLYTA ).</li><li>if you are taking strong CYP3A inhibitors (see Other medicines and VANFLYTA ).</li><li>if you have or have had fever, cough, chest pain, shortness of breath, tiredness or pain when urinating.</li></ul><p>Monitoring during treatment with VANFLYTA Blood tests Your doctor will perform regular blood tests during treatment with VANFLYTA to check your blood cells (white blood cells, red blood cells, and platelets) and electrolytes (salts such as sodium, potassium, magnesium, calcium, chloride and bicarbonate in blood). Your doctor will check your electrolytes more often if you are experiencing diarrhoea or vomiting.</p><p>Electrocardiogram Before and during your treatment, your doctor will check your heart with an electrocardiogram (ECG) to make sure your heart is beating normally. ECGs will be done weekly initially and less often thereafter as decided by your doctor. Your doctor will check your heart more often if you are taking other medicines that prolong the QT interval (see Other medicines and VANFLYTA ).</p><p>Infections in patients older than 65 years Elderly patients are at increased risk for very serious infections when compared to younger patients, especially in the early treatment period. If you are older than 65 years of age you will be closely monitored for the occurrence of severe infections during induction.</p><p>Children and adolescents Do not give this medicine to children or adolescents below 18 years of age because there is not enough information about its use in this age group.</p><p>Other medicines and VANFLYTA<br/>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, vitamins, antacids (medicines for heartburn and stomach acidity) and herbal supplements. This is because some medicines can affect how VANFLYTA works.</p><p>In particular, the following medicines may increase the risk of side effects with VANFLYTA by increasing the levels of this medicine in the blood:</p><ul><li>certain medicines used to treat fungal infections such as itraconazole, posaconazole or voriconazole;</li><li>certain antibiotics such as clarithromycin or telithromycin;</li><li>nefazodone, a medicine used to treat major depression.</li></ul><p>The following medicines may reduce the effectiveness of VANFLYTA:</p><ul><li>certain medicines used to treat tuberculosis such as rifampicin;</li><li>certain medicines used to treat seizures or epilepsy such as carbamazepine, primidone, phenobarbital or phenytoin;</li><li>certain medicines to treat prostatic cancer such as apalutamide and enzalutamide;</li><li>mitotane a medicine used for the treatment of symptoms of tumours of the adrenal glands;</li><li>bosentan a medicine used to treat high blood pressure in the lungs (pulmonary arterial hypertension);</li><li>St. John s Wort (Hypericum perforatum) an herbal product used for anxiety and mild depression.</li></ul><p>Certain medicines use to treat HIV may either increase the risk of side effects (e.g., ritonavir) or reduce the effectiveness (e.g., efavirenz or etravirine) of VANFLYTA.</p><p>QT interval prolonging medicinal products Co-administration of VANFLYTA with other medicinal products that prolong the QT interval may further increase the risk of QT prolongation. Examples of QT prolonging medicinal products include but are not limited to antifungal azoles, ondansetron, granisetron, azithromycin, pentamidine, doxycycline, moxifloxacin, atovaquone, prochlorperazine and tacrolimus.</p><p>Pregnancy, breast-feeding and fertility</p><p>Pregnancy</p><p>You should not take VANFLYTA during pregnancy. This is because it may harm your unborn baby. Women who are able to become pregnant should have a pregnancy test within 7 days before taking this medicine.</p><p>Women should use effective contraception during treatment with VANFLYTA and for at least 7 months after stopping treatment. Men should use effective contraception during treatment with VANFLYTA and for at least 4 months after stopping treatment.</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>Breast-feeding</p><p>Do not breast-feed during treatment with VANFLYTA, and for at least 5 weeks after stopping treatment. This is because it is not known if VANFLYTA passes into your breast milk (see Do not take VANFLYTA ). If you are breast-feeding, ask your doctor, pharmacist or nurse for advice before taking this medicine.</p><p>Fertility</p><p>VANFLYTA may reduce fertility in women and men. You should discuss this with your doctor before starting treatment.</p><p>Driving and using machines VANFLYTA is unlikely to affect your ability to drive or use machines.</p></div>"
}
},
{
"title" : "3. How to take vanflyta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take vanflyta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much VANFLYTA to take Your doctor or pharmacist will tell you exactly how much VANFLYTA to take. Do not change your dose or stop taking VANFLYTA without talking to your doctor first.</p><p>Usually you will start by taking 35.4 mg (two 17.7 mg tablets) once daily for 2 weeks during each cycle of chemotherapy. The maximum recommended dose is 53 mg once daily.</p><p>Your doctor may start you on a lower dose of one 17.7 mg tablet once daily if you are taking certain other medicines.</p><p>After your chemotherapy is completed your doctor may change your dose to one 26.5 mg tablet once daily for 2 weeks and then increase your dose to 53 mg (two 26.5 mg tablets) once daily going forward depending on how you respond to VANFLYTA.</p><p>Your doctor may temporarily interrupt treatment or change your dose based on blood tests, side effects or other medicines you may be taking.</p><p>Your doctor will discontinue your treatment if you are having a stem cell transplant. Your doctor will tell you when to stop taking your medicine and when to restart it.</p><p>Taking this medicine</p><ul><li>Take VANFLYTA by mouth - either with or without food.</li><li>Take VANFLYTA at about the same time each day. This will help you remember to take your medicine.</li><li>If you vomit after you take this medicine, do not take any more tablets until your next scheduled dose.</li></ul><p>How long to take VANFLYTA Continue taking VANFLYTA for as long as your doctor tells you. Your doctor will regularly monitor your condition to check that the treatment is continuing to work.</p><p>If you have any questions about how long to take VANFLYTA, talk to your doctor or pharmacist.</p><p>If you take more VANFLYTA than you should If you accidentally take more tablets than you should, or if someone else accidentally takes your medicine, talk to a doctor straightaway or go to a hospital and take this package leaflet with you. Medical treatment may be necessary.</p><p>If you forget to take VANFLYTA<br/>If you forget to take VANFLYTA, take it as soon as possible on the same day. Take your next dose at your usual time on the next day.</p><p>Do not take an extra dose (two doses on the same day) to make up for a forgotten dose.</p><p>If you stop taking VANFLYTA Stopping your treatment with VANFLYTA may cause your condition to become worse. Do not stop taking your medicine unless your doctor tells you to do so.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects Tell your doctor, pharmacist or nurse immediately if you notice the following side effects:</p><ul><li>feeling dizzy, lightheaded or faint. These could be signs of a heart problem called prolonged QT interval (abnormal electrical activity of the heart that affects its rhythm).</li><li>fever, cough, chest pain, shortness of breath, tiredness or pain when urinating. These could be signs of an infection or febrile neutropenia (low white blood cell counts with fever).</li></ul><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>Increase in alanine aminotransferase (abnormal liver enzyme results)</li><li>Thrombocytopenia (low levels of blood platelets)</li><li>Anaemia (low levels of red blood cells)</li><li>Neutropenia (low levels of neutrophils, a type of white blood cell)</li><li>Diarrhoea</li><li>Nausea (feeling sick)</li><li>Abdominal (stomach) pain</li><li>Headache</li><li>Vomiting</li><li>Oedema (swelling of the face, arms and legs)</li><li>Upper respiratory tract infections (nose and throat infections)</li><li>Decreased appetite</li><li>Epistaxis (severe nosebleeds)</li><li>Fungal infections</li><li>Herpes infections</li><li>Dyspepsia (indigestion)</li><li>Bacteraemia (bacteria in the blood)</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>Pancytopenia (low levels in all types of blood cells)</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>Cardiac arrest (heart stops beating)</li><li>Ventricular fibrillation (dangerous, irregular and uncoordinated contractions of the lower chambers of the heart)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store vanflyta",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store vanflyta"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not use this medicine if you notice any damage to the packaging or if there are any signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What VANFLYTA contains</p><ul><li>The active substance is quizartinib. VANFLYTA 17.7 mg: Each film-coated tablet contains 17.7 mg quizartinib (as dihydrochloride). VANFLYTA 26.5 mg: Each film-coated tablet contains 26.5 mg quizartinib (as dihydrochloride).</li><li>The other ingredients are: VANFLYTA 17.7 mg: Tablet core: Hydroxypropylbetadex, microcrystalline cellulose, magnesium stearate Film-coating: Hypromellose, talc, triacetin, titanium dioxide VANFLYTA 26.5 mg: Tablet core: Hydroxypropylbetadex, microcrystalline cellulose, magnesium stearate Film-coating: Hypromellose, talc, triacetin, titanium dioxide, yellow iron oxide</li></ul><p>What VANFLYTA looks like and contents of the pack VANFLYTA 17.7 mg film-coated tablets (tablets) are white, round and with DSC 511 on one side, and available in cartons containing 14 x 1 or 28 x 1 film-coated tablets in aluminium/aluminium perforated unit dose blisters.</p><p>VANFLYTA 26.5 mg film-coated tablets (tablets) are yellow, round and with DSC 512 on one side, and available in cartons containing 14 x 1, 28 x 1 or 56 x 1 film-coated tablets in aluminium/aluminium perforated unit dose blisters.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Daiichi Sankyo Europe GmbH Zielstattstrasse 81379 Munich Germany</p><p>Manufacturer Daiichi Sankyo Europe GmbH Luitpoldstrasse 1 85276 Pfaffenhofen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Daiichi Sankyo Belgium N.V.-S.A T l/Tel: +32-(0) 2 227 18 Lietuva Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0</p><p>Daiichi Sankyo Europe GmbH Te .: +49-(0) 89 7808 0 Luxembourg/Luxemburg Daiichi Sankyo Belgium N.V.-S.A T l/Tel: +32-(0) 2 227 18 esk republika Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Magyarorsz g Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 Danmark Daiichi Sankyo Nordics ApS Tlf: +45 (0) 33 68 19 Malta Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Deutschland Daiichi Sankyo Deutschland GmbH Tel: +49-(0) 89 7808 0 Nederland Daiichi Sankyo Nederland B.V. Tel: +31-(0) 20 4 07 20 Eesti Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Norge Daiichi Sankyo Nordics ApS Tlf: +47 (0) 21 09 38<br/>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 sterreich Daiichi Sankyo Austria GmbH Tel: +43-(0) 1 4858642 0 Espa a Daiichi Sankyo Espa a, S.A. Tel: +34 91 539 99 Polska Daiichi Sankyo Europe GmbH Tel.: +49-(0) 89 7808 0 France Daiichi Sankyo France S.A.S T l: +33 (0) 1 55 62 14 Portugal Daiichi Sankyo Portugal, Unip. LDA Tel: +351 21 4232Hrvatska Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Rom nia Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Ireland Daiichi Sankyo Ireland Ltd Tel: +353-(0) 1 489 3Slovenija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 sland Daiichi Sankyo Nordics ApS S mi: +354 5357Slovensk republika Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 Italia Daiichi Sankyo Italia S.p.A. Tel: +39-06 85 2Suomi/Finland Daiichi Sankyo Nordics ApS Puh/Tel: +358 (0) 9 3540 7<br/>Daiichi Sankyo Europe GmbH : +49-(0) 89 7808 0 Sverige Daiichi Sankyo Nordics ApS Tel: +46 (0) 40 699 2Latvija Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0 United Kingdom (Northern Ireland) Daiichi Sankyo Europe GmbH Tel: +49-(0) 89 7808 0</p><p>This leaflet was last revised in .</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp1ff94cd25db3b18c09de52395c558d2d",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp1ff94cd25db3b18c09de52395c558d2d",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp1ff94cd25db3b18c09de52395c558d2d\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp1ff94cd25db3b18c09de52395c558d2d</b></p><a name=\"mp1ff94cd25db3b18c09de52395c558d2d\"> </a><a name=\"hcmp1ff94cd25db3b18c09de52395c558d2d\"> </a><a name=\"mp1ff94cd25db3b18c09de52395c558d2d-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/23/1768/001-005</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: VANFLYTA 17.7 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/23/1768/001-005"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "VANFLYTA 17.7 mg film-coated tablets",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
